These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7582472)

  • 1. Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability.
    Madeddu P; Anania V; Varoni MV; Parpaglia PP; Demontis MP; Fattaccio MC; Palomba D; Pollock D; Glorioso N
    Br J Pharmacol; 1995 Jun; 115(4):557-62. PubMed ID: 7582472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.
    Hilditch A; Hunt AA; Gardner CJ; Twissell DJ; Polley J; Travers A; Drew GM; Middlemiss D; Ross BC; Robertson MJ
    Br J Pharmacol; 1994 Jan; 111(1):137-44. PubMed ID: 8012689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT1 receptor antagonist treatment caused persistent arterial functional changes in young spontaneously hypertensive rats.
    Gillies LK; Lu M; Wang H; Lee RM
    Hypertension; 1997 Dec; 30(6):1471-8. PubMed ID: 9403569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
    Morita O; Kushida H; Kunihara M
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):880-7. PubMed ID: 7564332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
    Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
    Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
    Leenen FH; Yuan B
    Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blunted renal responses to angiotensin II infusion in lifetime captopril-treated spontaneously hypertensive rats.
    Wu JN; Tsai SY; Hsieh WY
    Chin J Physiol; 2001 Jun; 44(2):59-65. PubMed ID: 11530945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular organ injuries in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohno E; Furukata S; Sudo Y; Nakano N; Takahashi T; Ono H; Matsuoka H
    Int Heart J; 2010; 51(5):359-64. PubMed ID: 20966610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
    Bunting MW; Widdop RE
    Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
    Inada Y; Murakami M; Kaido K; Nakao K
    Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic effects of central and systemic administration of losartan on blood pressure and baroreceptor reflex in spontaneously hypertensive rats.
    Kawano Y; Yoshida K; Matsuoka H; Omae T
    Am J Hypertens; 1994 Jun; 7(6):536-42. PubMed ID: 7917152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of orally administered ABBOTT-81988, an angiotensin II antagonist, in conscious spontaneously hypertensive rats.
    Lee JY; Warner RB; Brune ME; Adler AL; Winn M; De B; Zydowsky TM; Opgenorth TJ; Kerkman DJ; DeBernardis JF
    Am J Hypertens; 1994 Nov; 7(11):975-83. PubMed ID: 7848624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular dimensions in spontaneously hypertensive rats: effects of AT1 antagonism.
    Kett MM; Alcorn D; Bertram JF; Anderson WP
    J Hypertens; 1996 Jan; 14(1):107-13. PubMed ID: 12013482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central DuP 753 does not lower blood pressure in spontaneously hypertensive rats.
    DePasquale MJ; Fossa AA; Holt WF; Mangiapane ML
    Hypertension; 1992 Jun; 19(6 Pt 2):668-71. PubMed ID: 1592465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure development of the spontaneously hypertensive rat after concurrent manipulations of dietary Ca2+ and Na+. Relation to intestinal Ca2+ fluxes.
    McCarron DA; Lucas PA; Shneidman RJ; LaCour B; Drüeke T
    J Clin Invest; 1985 Sep; 76(3):1147-54. PubMed ID: 4044829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of chronic inhibition of calcium channel and angiotensin II type 1-receptor on aldosterone synthesis in spontaneously hypertensive rats.
    Otsuka F; Ogura T; Kataoka H; Kishida M; Takahashi M; Mimura Y; Yamauchi T; Makino H
    J Steroid Biochem Mol Biol; 2000 Oct; 74(3):125-36. PubMed ID: 11086231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril.
    Wu JN; Berecek KH
    Hypertension; 1993 Aug; 22(2):139-46. PubMed ID: 8340149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
    Jackson EK; Dubinion JH; Mi Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
    Ishiguro K; Sasamura H; Sakamaki Y; Itoh H; Saruta T
    Hypertens Res; 2007 Jan; 30(1):63-75. PubMed ID: 17460373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.